• Publications
  • Influence
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphomaExpand
  • 577
  • 21
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, thisExpand
  • 608
  • 18
  • PDF
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
BACKGROUND Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface antigens represent a potentially effective new therapy for lymphomas. We assessed the biodistribution, toxicity, andExpand
  • 656
  • 16
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Abstract Anti-CD20 monoclonal antibodies have been successfully employed in the clinical treatment of non-Hodgkin's lymphomas in both unmodified and radiolabeled forms. Previous publications haveExpand
  • 392
  • 16
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Seven murine monoclonal antibodies (MoAbs) recognizing differentiation antigens present on B-lymphocytes were analyzed in preclinical studies for their potential use for antibody-targeted therapy ofExpand
  • 266
  • 15
  • PDF
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
  • 315
  • 14
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
BACKGROUND Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugateExpand
  • 153
  • 14
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
PURPOSE To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients withExpand
  • 554
  • 13
New treatment options have changed the survival of patients with follicular lymphoma.
BACKGROUND The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is considered incurable.Expand
  • 363
  • 13
Evaluation and management of chylous ascites.
Twenty-eight cases of chylous ascites occurring over the past 20 years are analyzed for clinical presentation, cause, yield of diagnostic procedure used, and response to therapy. Malignancies wereExpand
  • 263
  • 13